现货大促销,价格低至8折起,量大更优惠,详细咨询客服
全部分类
全部分类
  • PLX7904
PLX7904的可视化放大

PLX7904

A RAF inhibitor

原价
¥937-937
价格
750-750
PLX7904的二维码

所有产品仅用于科学研究,我们不为任何个人用途提供产品和服务

询价有惊喜,量大更优惠 点击这里给我发消息

  • 库存: 现货
可选包装 >>>
首页
  • 货号: ajci4890
  • CAS: 1393465-84-3
  • 别名: PB04
  • 分子式: C24H22F2N6O3S
  • 分子量: 512.53
  • 纯度: >98%
  • 溶解度: DMSO: >5mg/ml
  • 储存: Store at -20°C
  • 库存: 现货

Background

IC50: 0.17, 0.53, and 0.16 μM for A375, COLO829 and COLO205 cell lines, respectively.


PLX7904 is a potent and selective BRAF inhibitor.


Oncogenic activation of BRAF leads to cancer growth by constitutively promoting RAS-independent mitogen-activated protein kinase pathway signalling. Therefore, BRAF inhibitors have provided substantially improved treatment of metastatic melanoma.


In vitro: Previous study showed that PLX7904 could inhibit the in-vitro growth of two melanoma cell lines (A375 and COLO829) and an additional human colorectal cancer cell line COLO205 expressed BRAFV600E. The gene expression changes in B9 cells treated with vemurafenib and PLX7904 were compared, and results demonstrated that vemurafenib could alter transcription of 191 mouse genes by at least 1.9-fold, while PLX7904 had minimal effects. Moreover, both vemurafenib and its analogue PLX4720 werer able to stimulate B9 colony formation, whereas PLX7904 was not [1].


In vivo: Animal study showed that both PLX7904 and vemurafenib could produce similar anti-tumour effects in a subcutaneous COLO205 xenograft model with matching doses at 25 mg/kg twice daily and plasma exposures. In addition, when evaluated in vivo, subcutaneous B9-tumour growth was accelerated by vemurafenib but not by PLX7904 when administered at the same dose [1].


Clinical trial: Up to now, PLX7904 is still in the preclinical development stage.

Reference:
[1] Zhang C et al.? RAF inhibitors that evade paradoxical MAPK pathway activation. Nature.2015 Oct 22;526(7574):583-6.

Protocol

Cell experiment:

For MTT assays, 2×103 cells are seeded in triplicate in 96 wells in their regular culture medium (containing PLX4720 for PRT lines). Next day, cells are washed twice with PBS and then the medium is replenished containing the indicated RAF inhibitor. Medium is changed 48 hours later and after a further 48 hours, 10 μL of 5 mg/mL MTT reagent is added to wells, and incubated for three hours. Formazan crystals are then solubilized overnight with a 1:10 dilution of 0.1 M glycine (pH 10.5) in DMSO. Wells are then analyzed at 450 nM in a Multiskan? Spectrum spectrophotometer. Results depicted are normalized to DMSO conditions and are a composite of three independent experiments. Error bars shown are representative of the standard error of mean (SEM).

Animal experiment:

COLO205 tumour cells are cultured in DMEM 10% FBS 1% penicillin/streptomycin supplemented with bovine insulin, at 37°C. Balb/C nude mice, female, 6-8 weeks old, weighing approximately 18-22 g, are inoculated subcutaneously at the right flank with COLO205 tumour cells (5×106) in 0.1 mL of PBS mixed with matrigel (50:50) for tumour development. The treatment is started when mean tumour size reach approximately 100 mm3, with eight mice in each treatment group randomized to balance the average weight and tumour size. B9 cells are expanded in DMEM 10% FBS 1% penicillin/streptomycin. Upon trypsinization the cells are washed three times with 20 mL RPMI, and after the final centrifugation are re-suspended, counted, and adjusted by volume to a final concentration of 5×107 cells per millilitre. B9 xenografts are started by injection of 5×106 cells subcutaneously in 6- to 7-week-old female nude Balb/c mice. Compound dosing starts when the average size of tumours reach 50-70 mm3. Animals are equally distributed over treatment groups (n=10) to balance the average tumour size and body weight. Animals are dosed orally for days 1-14 twice daily and days 15-28 once daily with vehicle, vemurafenib 50 mg per kg, or PLX7904 50 mg per kg. 12-O-tetradecanoylphorbol-13-acetate (TPA) is put on the skin of all mice twice a week during weeks 3 and 4 at a dose of 2 μg in 200 μL acetone.

参考文献:

[1]. Zhang C, et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature. 2015 Oct 22;526(7574):583-586.
[2]. Basile KJ, et al. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell Melanoma Res. 2014 May;27(3):479-84
[3]. Le K, et al. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res. 2013 Jul;26(4):509-17

动态评分

0.0

没有评分数据
没有评价数据
一键回到顶部
展开 收缩
安捷凯在线客服